Avricore Health Inc. announced that patient testing has begun on the first deployment of the new HealthTabTM-integrated Afinion 2TM analyzers in the initial Shoppers Drug Mart® pharmacy location as part of its previously announced effort to screen for diabetes and cardiovascular disease, demonstrating strong demand, smooth workflow, and reliable system operations. To prepare for the full public launch of the program, announced in May of this year, a first store was selected to receive the system to begin beta-testing HealthTabTM's systems, including the first patient tests. This work has successfully demonstrated that the very first installation of HealthTabTM with the Afinion 2TM analyzers is ready for prime-time, with HealthTabTM and the instruments performing well. So successful was the initial week that more than 90 patients were tested and over 600 results were reported over the initial trial period between July 5, 2021 to July 18, 2021 at this single location. In May 2021, HealthTabTM signed a master agreement with Shoppers Drug Mart Inc. to pilot the HealthTabTM platform. This agreement allows patients access to point-of-care blood screening and health-data management for potential risks for developing diabetes and cardiovascular conditions through the HealthTabTM-integrated Afinion 2TM analyzers by Abbott Rapid Diagnostics. All locations have now received their HealthTabTM systems and are being prepared to be online as soon.